Atogepant + Ubrogepant
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Episodic Migraine
Conditions
Episodic Migraine
Trial Timeline
Mar 7, 2022 → Apr 4, 2023
NCT ID
NCT05264129About Atogepant + Ubrogepant
Atogepant + Ubrogepant is a approved stage product being developed by AbbVie for Episodic Migraine. The current trial status is completed. This product is registered under clinical trial identifier NCT05264129. Target conditions include Episodic Migraine.
What happened to similar drugs?
2 of 15 similar drugs in Episodic Migraine were approved
Approved (2) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05892757 | Phase 1 | Completed |
| NCT05264129 | Approved | Completed |
| NCT04818515 | Phase 1 | Completed |
Competing Products
19 competing products in Episodic Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DFN-11 | Dr. Reddy's Laboratories | Phase 3 | 37 |
| Galcanezumab | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 44 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 40 |
| BOTOX + Placebo | AbbVie | Phase 3 | 32 |
| Atogepant 60 mg | AbbVie | Phase 3 | 40 |
| Atogepant + Placebo-Matching Atogepant | AbbVie | Phase 3 | 47 |
| SOM230 + Placebo | Novartis | Phase 2 | 27 |
| AMG334 + Oral Prophylactic | Novartis | Approved | 43 |
| AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS) | Novartis | Phase 3 | 40 |
| Erenumab | Novartis | Phase 3 | 40 |
| Placebo + AMG 301 | Amgen | Phase 2 | 35 |
| Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride) | Pfizer | Phase 1 | 29 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 44 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 37 |
| Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A | Ipsen | Phase 3 | 41 |
| IPN10200 + IPN10200 dose A + IPN10200 dose B | Ipsen | Phase 2 | 39 |
| Methylprednisolone | Brain Biotech | Approved | 33 |